Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268107 · ClinicalTrials.gov registry record · Phase 4
Ethnic Differences in Mechanisms of Action of Dupilumab
A Phase 4 study of Atopic Dermatitis, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05268107: Recruiting Phase 4 study of Atopic Dermatitis, sponsored by University of Michigan.
NCT05268107 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 30 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05268107, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic differences in both immune and stromal cells contribute to variability in AD presentation and response to anti-interleukin-4 receptor (IL-4R) inhibition with dupilumab.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
What NCT05268107 shows while recruiting
NCT05268107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05268107 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05268107 about?
NCT05268107 is a clinical study titled "Ethnic Differences in Mechanisms of Action of Dupilumab". Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD...
What is the current status of trial NCT05268107?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-01-25. Estimated completion is 2027-06.
What conditions does trial NCT05268107 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05268107?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05268107?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05268107 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05268107's enrollment target sits among peer trials
30 120th of 150 higher than 25 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI